Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity

Biochemical Pharmacology

Volumn 72, Issue 11, 2006, Pages 1453-1459

  Tsay, Gregory J ^a   Zouali, Moncef ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b INSERM   (France)

Author keywords

Autoimmunity; Human parvovirus B19; Immune subversion; Lupus; Rheumatoid arthritis; Signaling

Indexed keywords

ANTIBODY TITER; APOPTOSIS; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CHRONIC ARTHRITIS; DERMATOMYOSITIS; DNA REPLICATION; ERYTHROID CELL; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LEUKOPENIA; MITOCHONDRION; NONHUMAN; PARVOVIRUS; POLYMYOSITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; VASCULITIS; VIRUS VIRULENCE;

APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); VIRAL NONSTRUCTURAL PROTEINS;

EID: 33750602485     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.04.023     Document Type: Article

References (70)

1. Rose N.R. Mechanisms of autoimmunity. Semin Liver Dis 22 (2002) 387-394
2. In: Zouali M. (Ed). Molecular autoimmunity (2005), Springer Science/Business Media, Inc., New York 437
3. Heegaard E.D., and Brown K.E. Human parvovirus B19. Clin Microbiol Rev 15 (2002) 485-505
4. Brown K.E., Anderson S.M., and Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262 (1993) 114-117
5. Weigel-Kelley K.A., Yoder M.C., and Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol 75 (2001) 4110-4116
6. Takahashi Y., Murai C., Shibata S., Munakata Y., Ishii T., Ishii K., et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95 (1998) 8227-8232
7. White D.G., Woolf A.D., Mortimer P.P., Cohen B.J., Blake D.R., and Bacon P.A. Human parvovirus arthropathy. Lancet 1 (1985) 419-421
8. Reid D.M., Reid T.M., Brown T., Rennie J.A., and Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet 1 (1985) 422-425
9. Naides S.J. Rheumatic manifestations of parvovirus B19 infection. Rheum Dis Clin North Am 24 (1998) 375-401
10. Dijkmans B.A., van Elsacker-Niele A.M., Salimans M.M., van Albada-Kuipers G.A., de Vries E., and Weiland H.T. Human parvovirus B19 DNA in synovial fluid. Arthritis Rheum 31 (1988) 279-281
11. Kandolf R., Kirschner P., Hofschneider P.H., and Vischer T.L. Detection of parvovirus in a patient with "reactive arthritis" by in situ hybridization. Clin Rheumatol 8 (1989) 398-401
12. Saal J.G., Steidle M., Einsele H., Muller C.A., Fritz P., and Zacher J. Persistence of B19 parvovirus in synovial membranes of patients with rheumatoid arthritis. Rheumatol Int 12 (1992) 147-151
13. Vigeant P., Menard H.A., and Boire G. Chronic modulation of the autoimmune response following parvovirus B19 infection. J Rheumatol 21 (1994) 1165-1167
14. Rodrigo de Liria C., Mendez M., Olive A., Junca J., Prats J., and Tena X. Parvovirus infection mimicking a systematic onset of juvenile chronic arthritis (Still's disease). Clin Exp Rheumatol 14 (1996) 105-106
15. Nesher G., Rubinow A., and Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arthritis: a retrospective study. Clin Exp Rheumatol 15 (1997) 303-306
16. Trapani S., Ermini M., and Falcini F. Human parvovirus B19 infection: its relationship with systemic lupus erythematosus. Semin Arthritis Rheum 28 (1999) 319-325
17. Mayo D.R., and Vance Jr. D.W. Parvovirus B19 as the cause of a syndrome resembling Lyme arthritis in adults. N Engl J Med 324 (1991) 419-420
18. Finkel T.H., Torok T.J., Ferguson P.J., Durigon E.L., Zaki S.R., Leung D.Y., et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?. Lancet 343 (1994) 1255-1258
19. Kerr J.R. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann Rheum Dis 59 (2000) 672-683
20. Meyer O. Parvovirus B19 and autoimmune diseases. Joint Bone Spine 70 (2003) 6-11
21. Lehmann H.W., von Landenberg P., and Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev 2 (2003) 218-223
22. Chou C.C., Chen Y.N., and Li C.S. Congener-specific polychlorinated biphenyls in cetaceans from Taiwan waters. Arch Environ Contam Toxicol 47 (2004) 551-560
23. von Poblotzki A., Hemauer A., Gigler A., Puchhammer-Stockl E., Heinz F.X., Pont J., et al. Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis 172 (1995) 1356-1359
24. Heegaard E.D., Rasksen C.J., and Christensen J. Detection of parvovirus B19 NS1-specific antibodies by ELISA and western blotting employing recombinant NS1 protein as antigen. J Med Virol 67 (2002) 375-383
25. Short C.L. The antiquity of rheumatoid arthritis. Arthritis Rheum 17 (1974) 193-205
26. Rothschild B.M., Turner K.R., and DeLuca M.A. Symmetrical erosive peripheral polyarthritis in the Late Archaic Period of Alabama. Science 241 (1988) 1498-1501
27. Rothschild B.M., Woods R.J., Rothschild C., and Sebes J.I. Geographic distribution of rheumatoid arthritis in ancient North America: implications for pathogenesis. Semin Arthritis Rheum 22 (1992) 181-187
28. Altschuler E.L. Parvovirus B19 and the pathogenesis of rheumatoid arthritis: a case for historical reasoning. Lancet 354 (1999) 1026-1027
29. Chorba T., and Anderson L.J. Erythema infectiosum (fifth disease). Clin Dermatol 7 (1989) 65-74
30. Hasler P., and Zouali M. B cell receptor signaling and autoimmunity. FASEB J 15 (2001) 2085-2098
31. Zouali M., and Sarmay G. B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum 50 (2004) 2730-2741
32. Hasler P., and Zouali M. Immune receptor signaling, aging, and autoimmunity. Cell Immunol 233 (2005) 102-108
33. Peeva E., and Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 101 (2005) 123-143
34. Lim P., and Zouali M. Pathogenic autoantibodies: emerging insights into tissue injury. Immunol Lett 103 (2006) 17-26
35. Walsh K.J., Armstrong R.D., and Turner A.M. Brachial plexus neuropathy associated with human parvovirus infection. Br Med J (Clin Res Ed) 296 (1988) 896
36. Frickhofen N., Abkowitz J.L., Safford M., Berry J.M., Antunez-de-Mayolo J., Astrow A., et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 113 (1990) 926-933
37. Anderson M.J., Higgins P.G., Davis L.R., Willman J.S., Jones S.E., Kidd I.M., et al. Experimental parvoviral infection in humans. J Infect Dis 152 (1985) 257-265
38. Lunardi C., Tiso M., Borgato L., Nanni L., Millo R., De Sandre G., et al. Chronic parvovirus B19 infection induces the production of anti-virus antibodies with autoantigen binding properties. Eur J Immunol 28 (1998) 936-948
39. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
40. Ray N.B., Nieva D.R., Seftor E.A., Khalkhali-Ellis Z., and Naides S.J. Induction of an invasive phenotype by human parvovirus B19 in normal human synovial fibroblasts. Arthritis Rheum 44 (2001) 1582-1586
41. Emlen W., Niebur J., and Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 152 (1994) 3685-3692
42. Huck S., Deveaud E., Namane A., and Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J 13 (1999) 1415-1422
43. Casciola-Rosen L., Andrade F., Ulanet D., Wong W.B., and Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 190 (1999) 815-826
44. Zouali M. Taming lupus. Sci Am 292 (2005) 58-65
45. Ozawa K., Ayub J., Kajigaya S., Shimada T., and Young N. The gene encoding the nonstructural protein of B19 (human) parvovirus may be lethal in transfected cells. J Virol 62 (1988) 2884-2889
46. Raab U., Beckenlehner K., Lowin T., Niller H.H., Doyle S., and Modrow S. NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Sp1/Sp3. Virology 293 (2002) 86-93
47. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1 (2002) 639-649
48. Pinkoski M.J., Waterhouse N.J., and Green D.R. Mitochondria apoptosis and autoimmunity. Curr Dir Autoimmun 9 (2006) 55-73
49. Hsu T.C., Wu W.J., Chen M.C., and Tsay G.J. Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells. Scand J Infect Dis 36 (2004) 570-577
50. Fan M.M., Tamburic L., Shippam-Brett C., Zagrodney D.B., and Astell C.R. The small 11-kDa protein from B19 parvovirus binds growth factor receptor-binding protein 2 in vitro in a Src homology 3 domain/ligand-dependent manner. Virology 291 (2001) 285-291
51. Tan S.L., Nakao H., He Y., Vijaysri S., Neddermann P., Jacobs B.L., et al. NS5A a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 96 (1999) 5533-5538
52. Macdonald A., Crowder K., Street A., McCormick C., and Harris M. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol 85 (2004) 721-729
53. Saksela K., Cheng G., and Baltimore D. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef + viruses but not for down-regulation of CD4. EMBO J 14 (1995) 484-491
54. Manninen A., Hiipakka M., Vihinen M., Lu W., Mayer B.J., and Saksela K. SH3-Domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Virology 250 (1998) 273-282
55. Moffatt S., Tanaka N., Tada K., Nose M., Nakamura M., Muraoka O., et al. A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol 70 (1996) 8485-8491
56. Mitchell L.A. Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: common pathway in inflammatory sequelae of human parvovirus infections?. J Med Virol 14 (2002) 267-274
57. Hsu T.C., Tzang B.S., Huang C.N., Lee Y.J., Liu G.Y., Chen M.C., et al. Increased expression and secretion of IL-6 in human parvovirus B19 nonstructural protein (NS1) transfected COS-7 epithelial cells. Clin Exp Immunol 144 (2006) 152-157
58. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
59. Nigro G., Bastianon V., Colloridi V., Ventriglia F., Gallo P., D'Amati G., et al. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin Infect Dis 31 (2000) 65-69
60. Miyazawa K., Mori A., and Okudaira H. IL-6 synthesis by rheumatoid synoviocytes is autonomously upregulated at the transcriptional level. J Allergy Clin Immunol 103 (1999) S437-S444
61. Cooling L.L., Koerner T.A., and Naides S.J. Multiple glycosphingolipids determine the tissue tropism of parvovirus B19. J Infect Dis 172 (1995) 1198-1205
62. Fu Y., Ishii K.K., Munakata Y., Saitoh T., Kaku M., and Sasaki T. Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol 76 (2002) 5395-5403
63. Kerr J.R., Barah F., Mattey D.L., Laing I., Hopkins S.J., Hutchinson I.V., et al. Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82 (2001) 3011-3019
64. Hall W.W. Human T cell lymphotropic virus type I and cutaneous T cell leukemia/lymphoma. J Exp Med 180 (1994) 1581-1585
65. Scala G., Ruocco M.R., Ambrosino C., Mallardo M., Giordano V., Baldassarre F., et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 179 (1994) 961-971
66. Nishioka K., Maruyama I., Sato K., Kitajima I., Nakajima Y., and Osame M. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1 (1989) 441
67. Nakajima T., Aono H., Hasunuma T., Yamamoto K., Maruyama I., Nosaka T., et al. Overgrowth of human synovial cells driven by the human T cell leukemia virus type I tax gene. J Clin Invest 92 (1993) 186-193
68. Viau M., Longo N.S., Lipsky P.E., Bjorck L., and Zouali M. Specific in vivo deletion of B-cell subpopulations expressing human immunoglobulins by the B-cell superantigen protein L. Infect Immun 72 (2004) 3515-3523
69. Viau M., Longo N.S., Lipsky P.E., and Zouali M. Staphylococcal protein a deletes B-1a and marginal zone B lymphocytes expressing human immunoglobulins: an immune evasion mechanism. J Immunol 175 (2005) 7719-7727
70. Hasler P., and Zouali M. Subversion of B lymphocyte signaling by infectious agents. Genes Immun 4 (2003) 95-103